Amylyx Pharmaceuticals, Inc. AMLX
NASDAQ · United States · Health Technology
$29.10-0.18 (-0.61%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Bond markets have been shaken by 10-year Treasury yields hitting a 19-year high, which raises borrowing costs and forces investors to rethink where future returns might come from. That kind of reset often shifts attention toward businesses where earnings are expected to grow solidly and balance sheets still look healthy. This article highlights three stocks that fit that profile and explains how they may fit into a long-term growth plan. The three stocks covered next are only a small sample...
CAMBRIDGE, Mass., September 23, 2026--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
FRAMINGHAM, Mass., September 09, 2026--Tortugas Neuroscience ("Tortugas"), a clinical-stage central nervous system (CNS)-focused biotech company developing medicines with clinically validated mechanisms of action in indications with both substantial patient populations and high unmet need, today announced the appointment of Jim Frates to its Board of Directors and as Chair of the Audit Committee. A highly experienced biopharmaceutical leader who has served as chief financial officer (CFO) for mu
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.